Patent US4299813A successfully refreshed from Google Patents.
US4299813A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay kit and method
Assignee: Nova Pharmaceutical Corp
•
Filing: 1979-05-17
•
Granted: 1981-11-10
•
Expires: 1999-05-17
Abstract
Abstract Method and kit for determining levels of tricyclic antidepressants in body fluid, the method including the step of measuring inhibition of the binding of radioactive muscarinic cholinergic or radioactive histamine H 1 receptor binder to muscarinic cholinergic or histamine H 1 receptor material caused by tricyclic antidepressant present in the body fluid.
Inventors
- 👤 Solomon H. Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 08:41
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/9466; G01N33/58; G01N33/60; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/815
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
99 words
The method of determining the concentration of tricyclic antidepressant drugs and any active metabolites thereof in a body fluid containing same comprising the independent procedures of (a) mixing together muscarinic cholinergic receptor material, radioactive muscarinic cholinergic receptor binder and body fluid, and measuring the amount of the radioactive muscarinic cholinergic binder on the muscarinic cholinergic receptor material and (b) mixing together a concentration of a standard amount of non-radioactive muscarinic cholinergic receptor binder, muscarinic cholinergic receptor material and radioactive muscarinic cholinergic receptor binder and measuring the amount of radioactive muscarinic cholinergic receptor binder on the muscarinic cholinergic receptor material.
Claim 2
Independent Claim
99 words
The method of determining the concentration of tricyclic antidepressant drugs and any active metabolites thereof in a body fluid containing same comprising the independent procedures of (a) mixing together muscarinic cholinergic receptor material, radioactive muscarinic cholinergic receptor binder and body fluid, and measuring the amount of the radioactive muscarinic cholinergic binder on the muscarinic cholinergic receptor material and (b) mixing together a concentration of a standard amount of non-radioactive muscarinic cholinergic receptor binder, muscarinic cholinergic receptor material and radioactive muscarinic cholinergic receptor binder and measuring the amount of radioactive muscarinic cholinergic receptor binder on the muscarinic cholinergic receptor material.
Claim 3
Dependent Claim
47 words
The method of claim 1 in which the material, binder, and body fluid are permitted to remain together a time sufficient to produce sufficient binding of the binder, drugs and any active metabolites thereof in the body fluid to said receptor material prior to making the measurement.
Claim 4
Dependent Claim
30 words
The method of claim 1 in which the material, binder and body fluid are combined in the presence of sufficient buffer to produce a pH of about 6 to 9.
Claim 5
Dependent Claim
19 words
The method of claim 1 in which unbound binder and body fluid are removed as part of the measurement.
Claim 6
Dependent Claim
20 words
The method of claim 1, 2, 3 or 4 in which the body fluid is blood plasma or blood serum.
Claim 7
Dependent Claim
40 words
The method of claim 1 in which measuring of the amount of radioactive receptor binder on the receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radionuclide portion of the radioactive binder.
Claim 8
Dependent Claim
35 words
The method of claim 1 or 6 in which the concentration of drug and active metabolite is determined by reference to a standard curve representing percent inhibition of radioactive receptor binder vs. non-radioactive receptor binder.
Claim 9
Dependent Claim
17 words
The method of claim 1 in which the concentration of body fluid is less than about 10%.
Claim 10
Dependent Claim
18 words
The method of claim 1 or 8 in which the body fluid is blood plasma or blood serum.
Claim 11
Dependent Claim
22 words
The method of claim 1, in which the amount of body fluid in the mixture containing same is greater than one microliter.
Claim 12
Dependent Claim
25 words
The method of claim 1 in which the unbound drug, unbound radioactive binder and body fluid are removed in determining the percent inhibition of binding.
Claim 13
Dependent Claim
28 words
The method of claim 1 in which the radioactive receptor binder is selected from the group consisting of radioactive labeled quinuclidinyl benzilate and radioactive labelled propylbenzilyl choline mustard.
Claim 14
Dependent Claim
13 words
The method of claim 1 in which the receptor material is brain tissue.
Claim 15
Dependent Claim
30 words
The method of claim 1 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 16
Dependent Claim
26 words
As a mercantile unit, a kit of at least one container of radioactive muscarinic cholinergic binder, muscarinic cholinergic receptor material, and standard non-radioactive muscarinic cholinergic binder.
Claim 17
Dependent Claim
26 words
As a mercantile unit, a kit of at least one container of radioactive muscarinic cholinergic binder, muscarinic cholinergic receptor material, and standard non-radioactive muscarinic cholinergic binder.
Claim 18
Dependent Claim
23 words
The kit of claim 15 in which the radioactive binder is selected from the group consisting of quinuclidinyl benzilate and propylbenzilyl choline mustard.
Claim 19
Dependent Claim
20 words
The kit of claim 15 or 16 in which the radioactive label is 3 H, 125 I or 131 I.
Claim 20
Independent Claim
105 words
The method of determining the concentration of tricyclic antidepressant drugs and any active metabolites thereof in a body fluid containing same comprising the independent procedures of (a) mixing together histamine H 1 receptor material, radioactive histamine H 1 receptor binder and body fluid, and measuring the amount of the radioactive binder on the histamine H 1 receptor material and (b) mixing together a concentration of a standard amount of non-radioactive histamine H 1 receptor binder, histamine H 1 receptor material and radioactive histamine H 1 receptor binder and measuring the amount of radioactive histamine H 1 receptor binder on the histamine H 1 receptor material.
Claim 21
Independent Claim
105 words
The method of determining the concentration of tricyclic antidepressant drugs and any active metabolites thereof in a body fluid containing same comprising the independent procedures of (a) mixing together histamine H 1 receptor material, radioactive histamine H 1 receptor binder and body fluid, and measuring the amount of the radioactive binder on the histamine H 1 receptor material and (b) mixing together a concentration of a standard amount of non-radioactive histamine H 1 receptor binder, histamine H 1 receptor material and radioactive histamine H 1 receptor binder and measuring the amount of radioactive histamine H 1 receptor binder on the histamine H 1 receptor material.
Claim 22
Dependent Claim
47 words
The method of claim 18 in which the material, binder, and body fluid are permitted to remain together a time sufficient to produce sufficient binding of the binder, drugs and any active metabolites thereof in the body fluid to said receptor material prior to making the measurement.
Claim 23
Dependent Claim
30 words
The method of claim 19 in which the material, binder and body fluid are combined in the presence of sufficient buffer to produce a pH of about 6 to 9.
Claim 24
Dependent Claim
19 words
The method of claim 18 in which unbound binder and body fluid are removed as part of the measurement.
Claim 25
Dependent Claim
20 words
The method of claim 18, 19, 20 or 21 in which the body fluid is blood plasma or blood serum.
Claim 26
Dependent Claim
43 words
The method of claim 18 in which the percent inhibition measuring of the amount of radioactive receptor binder on the receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radionuclide portion of the radioactive binder.
Claim 27
Dependent Claim
36 words
The method of claim 18 or 23 in which the concentration of drug and active metabolite is determined by reference to a standard curve representing percent inhibition of radioactive receptor binder vs. drug non-radioactive receptor binder.
Claim 28
Dependent Claim
17 words
The method of claim 18 in which the concentration of body fluid is less than about 10%.
Claim 29
Dependent Claim
18 words
The method of claim 18 or 25 in which the body fluid is blood plasma or blood serum.
Claim 30
Dependent Claim
23 words
The method of claim 18, in which the amount of body fluid in the mixture containing same is greater than about one microliter.
Claim 31
Dependent Claim
27 words
The method of claim 18 or 25 in which the unbound drug, unbound radioactive binder and body fluid are removed in determining the percent inhibition of binding.
Claim 32
Dependent Claim
15 words
The method of claim 18 in which the radioactive receptor binder is radioactive labeled mepyramine.
Claim 33
Dependent Claim
13 words
The method of claim 18 in which the receptor material is brain tissue.
Claim 34
Dependent Claim
30 words
The method of claim 18 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 35
Dependent Claim
29 words
As a mercantile unit, a kit of at least one container of radioactive histamine H 1 binder, histamine H 1 receptor material, and standard nonradioactive histamine H 1 binder.
Claim 36
Dependent Claim
29 words
As a mercantile unit, a kit of at least one container of radioactive histamine H 1 binder, histamine H 1 receptor material, and standard nonradioactive histamine H 1 binder.
Claim 37
Dependent Claim
14 words
The kit of claim 32 in which the radioactive binder is radioactive labeled mepyramine.
Claim 38
Dependent Claim
20 words
The kit of claim 32 or 33 in which the radioactive label is 3 H, 125 I or 131 I.
References Cited (Backward Citations)
US4197288A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-11-09 | 1985-05-11 | 1985-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-11-09 | 1989-05-11 | 1989-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-11-09 | 1993-05-11 | 1993-11-10 | $7700.00 | Window Closed / Lapsed |